|Day Low/High||112.55 / 117.97|
|52 Wk Low/High||72.05 / 158.80|
This is one of those days when it may pay to walk away.
Keep an eye on the pattern of morning weakness and afternoon strength.
After yesterday's surprise pullback, this is the sort of consolidation we need.
If you play strong defense, be prepared to change course very quickly.
But it is all about timing, and so far there is no indication that this extended market is about to turn.
It will be interesting to see today if afternoon strength occurs once again.
TheStreet's Adam Feuerstein defends Sarepta Therapeutics
Market players are sorting out the winners and losers, and that produces good opportunities if we keep on digging.
These companies show signs of a change of direction.
Stocks were climbing at midday on Tuesday, and the Nasdaq moved further into record territory.
Sarepta Therapeutics provides early sales numbers for its drug to treat DMD, and they topped expectations.
Its members are skeptical about the market celebration and are not going to commit to a course of rate hikes until they have more data.
If the indices take out yesterday's lows I'll be very bearish very quickly.
I've got my eye on steel and biotechnology names to put cash to work.
2016 tweets by TheStreet's Adam Feuerstein kept us informed and entertained. From an unexpected twist on New Year's day with MannKind to J.P. Morgan's Healthcare conference to Bristol-Myers Squibb's oops!
The trading action remains quite tedious, though there are short-term opportunities out there.
You have to dig below the surface and develop a feel for what stocks are leading.
Equities are holding up well, despite concerns that good economic news increases the chances of a rate hike.
SeaDrill's chairman and top shareholder seems willing to lend a hand to keep the company's leverage in check.
Summit Therapetuics shares skyrocketed Tuesday on word that it has entered into an exclusive licensing agreement with drugmaker Sarepta Therapeutics.
We are seeing lower lows in the indices as I write.